97420511 - SCRIBE THERAPEUTICS

Information

• Trademark
• 97420511

• Source

• Serial Number

  97420511

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  May 20, 2022
  2 years ago

• Transaction Date

  December 15, 2024
  a month ago

• Status Date

  June 11, 2024
  7 months ago

• Published for Opposition Date

  April 25, 2023
  a year ago

• Location Date

  June 20, 2023
  a year ago

• First Use Anywhere Date

  October 01, 2020
  4 years ago

• First Use In Commerce Date

  October 01, 2020
  4 years ago

• Status Code

  731

• Current Location

  INTENT TO USE SECTION

  Employee Name

  DIBLE, IAN

• Attorney Docket Number

  333322-20000

  Attorney Name

  John Paul Oleksiuk

  Law Office Assigned Location Code

  M20

• Owners

  • Scribe Therapeutics, Inc.

Case File Statements

• GS0051: Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeutics, namely, diseases caused by genetic mutations and diseases and disorders for which gene modification would ameliorate or cure; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics, namely, for the diagnosis, prevention, and treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, and pain, and also for the prevention and treatment of cardiovascular, peripheral nervous system, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, and hematologic diseases and disorders, and cancer
• GS0441: Molecular diagnostic services in the nature of genetic testing for medical purposes; Medical diagnostic testing services in the field of human disease and human medical conditions
• DS0000: "THERAPEUTICS"
• GS0421: Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic transcriptional regulation, genetic transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, and therapeutic products and services; Design and development of engineered cells for use in scientific research and in drug discovery and development; Providing medical and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic transcriptional regulation, genetic transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering; Molecular diagnostic services in the nature of genetic testing for medical research purposes

Case File Event Statements

• 5/24/2022 - 2 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 5/25/2022 - 2 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 3/9/2023 - a year ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 3/16/2023 - a year ago

  4 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 3/16/2023 - a year ago

  5 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 3/16/2023 - a year ago

  6 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 3/16/2023 - a year ago

  7 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 3/16/2023 - a year ago

  8 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 4/5/2023 - a year ago

  9 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 4/25/2023 - a year ago

  10 - PUBLISHED FOR OPPOSITION Type: PUBO

• 4/25/2023 - a year ago

  11 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 6/20/2023 - a year ago

  12 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 12/10/2023 - a year ago

  13 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 12/10/2023 - a year ago

  14 - SOU EXTENSION 1 FILED Type: EXT1

• 12/10/2023 - a year ago

  15 - SOU EXTENSION 1 GRANTED Type: EX1G

• 6/11/2024 - 7 months ago

  17 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 6/13/2024 - 7 months ago

  20 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 12/12/2023 - a year ago

  16 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 6/11/2024 - 7 months ago

  19 - SOU EXTENSION 2 GRANTED Type: EX2G

• 6/11/2024 - 7 months ago

  18 - SOU EXTENSION 2 FILED Type: EXT2

• 12/15/2024 - a month ago

  21 - SOU TEAS EXTENSION RECEIVED Type: EEXT